SPOTLIGHT: GSK allows generic AIDS drug
GlaxoSmithKline says it's letting a Canadian drug company use two of its patented drugs in a combination HIV therapy for Rwanda. Apotex will make the combo--known as Apo-triAvir--using Glaxo's antiretrovirals lamivudine and zidovudine, plus Boehringer Ingelheim's nevirapine. The agreement was struck through Canada's Access to Medicines initiative, a three-year-old bit of legislation intended to help poor countries gain access to needed drugs, but until now has failed to do so. Report
Be the first to comment
More stories about GlaxoSmithKline
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

